Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study

Background Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate to-severe atopic dermatitis (AD) remains limited. Objectives This study aimed to evaluate the short-term effectiveness and safet...

Descripción completa

Detalles Bibliográficos
Autores: Armario Hita, José Carlos, Pereyra-Rodríguez, José-Juan, González-Quesada, Alicia, Herranz, Pedro, Suarez, Ricardo, Galán Gutiérrez, Manuel, Ruiz-Villaverde, Ricardo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/161664
Acceso en línea:https://hdl.handle.net/11441/161664
https://doi.org/10.1111/ijd.17344
Access Level:acceso abierto
Palabra clave:Atopic dermatitis
Treatment
Abrocitinib
JAK inhibitors
Spain
id ES_c66bded1dfef52f4bf3f656076fbcb42
oai_identifier_str oai:idus.us.es:11441/161664
network_acronym_str ES
network_name_str España
repository_id_str
spelling Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter studyArmario Hita, José CarlosPereyra-Rodríguez, José-JuanGonzález-Quesada, AliciaHerranz, PedroSuarez, RicardoGalán Gutiérrez, ManuelRuiz-Villaverde, RicardoAtopic dermatitisTreatmentAbrocitinibJAK inhibitorsSpainBackground Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate to-severe atopic dermatitis (AD) remains limited. Objectives This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD. Methods We conducted a retrospective multicenter study involving adult patients with moderate-to-severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters. Results The cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were na€ıve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma. Conclusions This first Spanish series assessing abrocitinib in real-world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well-tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.WileyMedicina2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/161664https://doi.org/10.1111/ijd.17344reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésInternational journal of dermatology, 1-7.https://onlinelibrary.wiley.com/doi/10.1111/ijd.17344info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1616642026-06-17T12:51:07Z
dc.title.none.fl_str_mv Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
title Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
spellingShingle Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
Armario Hita, José Carlos
Atopic dermatitis
Treatment
Abrocitinib
JAK inhibitors
Spain
title_short Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
title_full Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
title_fullStr Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
title_full_unstemmed Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
title_sort Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
dc.creator.none.fl_str_mv Armario Hita, José Carlos
Pereyra-Rodríguez, José-Juan
González-Quesada, Alicia
Herranz, Pedro
Suarez, Ricardo
Galán Gutiérrez, Manuel
Ruiz-Villaverde, Ricardo
author Armario Hita, José Carlos
author_facet Armario Hita, José Carlos
Pereyra-Rodríguez, José-Juan
González-Quesada, Alicia
Herranz, Pedro
Suarez, Ricardo
Galán Gutiérrez, Manuel
Ruiz-Villaverde, Ricardo
author_role author
author2 Pereyra-Rodríguez, José-Juan
González-Quesada, Alicia
Herranz, Pedro
Suarez, Ricardo
Galán Gutiérrez, Manuel
Ruiz-Villaverde, Ricardo
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv Atopic dermatitis
Treatment
Abrocitinib
JAK inhibitors
Spain
topic Atopic dermatitis
Treatment
Abrocitinib
JAK inhibitors
Spain
description Background Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate to-severe atopic dermatitis (AD) remains limited. Objectives This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD. Methods We conducted a retrospective multicenter study involving adult patients with moderate-to-severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters. Results The cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were na€ıve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma. Conclusions This first Spanish series assessing abrocitinib in real-world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well-tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/161664
https://doi.org/10.1111/ijd.17344
url https://hdl.handle.net/11441/161664
https://doi.org/10.1111/ijd.17344
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv International journal of dermatology, 1-7.
https://onlinelibrary.wiley.com/doi/10.1111/ijd.17344
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419071898910720
score 15,811543

Similares en LA Referencia